The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point

  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Omacor becomes Lovaza

    My pharmacist tells me that the prescription strength omega-3 fatty acid product called Omacor is having its name changed.

    The new name is Lovaza.

    Reliant Pharmaceuticals website confirms the name change, but only partially explains the rationale.

    The change will eliminate the risk of confusion with adenosine (Adenocard), which is used to treat certain heart arrhythmias.

    8/28/07 16:18 JR

    This entry was posted on Tuesday, August 28th, 2007 at 4:24 PM and is filed under Omega-3 Fatty Acids. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

    Leave a Comment

    You must be logged in to post a comment.

    « Deadly depression in people with heart failure
    FDA wants to rate UVA protection in sunscreen products »